Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times

被引：0
|
作者：
Ashwell, SG
Home, PD
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A118 / A118
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of once-weekly semaglutide vs once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    DeVries, J. H.
    Bain, S. C.
    Cariou, B.
    Rose, L.
    Axelsen, M.
    Rowe, E.
    Aroda, V. R.
    DIABETOLOGIA, 2016, 59 : S76 - S77
  • [42] Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
    Kann, P. H.
    Wascher, T.
    Zackova, V.
    Moeller, J.
    Medding, J.
    Szocs, A.
    Mokan, M.
    Mrevlje, F.
    Regulski, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2006, 114 (09) : 527 - 532
  • [43] Hypoglycaemia frequency and physiological response to double or triple doses of once-weekly insulin icodec versus once-daily insulin glargine in type 2 diabetes
    Pieber, T. R.
    Arfelt, K. N.
    Cailleteau, R.
    Thomsen, K. M. Due
    Hart, M.
    Mursic, I.
    Svehlikova, E.
    Urschitz, M.
    Haahr, H.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S333 - S333
  • [44] Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
    Roussel, Ronan
    d'Emden, Michael C.
    Fisher, Miles
    Javier Ampudia-Blasco, F.
    Stella, Peter
    Bizet, Florence
    Cali, Anna M. G.
    Wysham, Carol H.
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 448 - 452
  • [45] Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study
    King, A. B.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 69 - 71
  • [46] Improvement in HbA1c with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with type 1 diabetes
    Ashwell, S
    Amiel, S
    Bilous, R
    Heller, S
    Hepburn, D
    Home, P
    DIABETES, 2003, 52 : A442 - A442
  • [47] Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine
    Mathieu, C.
    Fulcher, G.
    Rao, P. V.
    Thomas, N.
    Endahl, L.
    Johansen, T.
    Lewin, A. J.
    Rosenstock, J.
    Pinget, M.
    Zinman, B.
    DIABETOLOGIA, 2010, 53 : S8 - S8
  • [48] Insulin Degludec, a New Generation Ultra-Long Acting Insulin, Used Once Daily or 3-Times Weekly in People with Type 2 Diabetes: Comparison to Insulin Glargine
    Zinman, Bernard
    Fulcher, Greg
    Rao, Paturi V.
    Thomas, Nihal
    Endahl, Lars
    Johansen, Thue
    Lewin, Andrew
    Rosenstock, Julio
    Pinget, Michel
    Mathieu, Chantal
    DIABETES, 2010, 59 : A11 - A11
  • [49] Technosphere® Insulin vs Insulin Lispro in Patients with Type 1 Diabetes Using Multiple Daily Injections
    Garg, Satish K.
    McGill, Janet B.
    Rosenstock, Julio
    Hirsch, Irl B.
    Petrucci, Richard E.
    Chang, Ping-Chung
    Boss, Anders H.
    Richardson, Peter C.
    Skyler, Jay S.
    DIABETES, 2011, 60 : A250 - A250
  • [50] Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in pediatric type 1 diabetes
    Alemzadeh, Ramin
    Parton, Elaine
    Holzum, Mary
    DIABETES, 2008, 57 : A498 - A498
12345